{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:32:33Z","timestamp":1789997553633,"version":"4.0.1"},"reference-count":14,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To describe the first 13\u00a0years of anti\u2010vascular endothelial growth factor (anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content>) therapy from the perspective of a public ophthalmic department serving a local community of almost one million people.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective registry study. Data from Oslo University Hospital, Norway were collected from 2006 through 2018. Hospital episode statistics were searched for episodes of care encompassing intravitreal anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content> procedures. Patient\u2010specific <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content> numbers, diagnoses, and drug codes were registered. In general, bevacizumab was used as first\u2010line treatment, with aflibercept reserved for resistant cases from 2013.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The number of unique patients treated per year increased from 130 in 2006 to 3428 in 2018. In 2018, 2488 (73%) patients had also received treatment the previous year. The number of yearly injections increased from 228 in 2006 to 25\u00a0570 in 2018. In 2018 the diagnosis macular degeneration constituted 69% of injections, diabetic retinopathy constituted\u00a015%, retinal vein occlusion constituted\u00a013%, and other diagnoses constituted\u00a03%. In the same year 49% of injections were with\u00a0bevacizumab, 46% with aflibercept, 4% with ranibizumab, and 1% with dexamethasone implants. The bevacizumab to aflibercept ratio was almost 1:1 for macular degeneration and diabetic retinopathy; for retinal vein occlusion the ratio was 13:7.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In 13\u00a0years there was an approximately 100\u2010fold increase in the number of yearly intravitreal injections. A majority of patients received long\u2010term treatment. Macular degeneration was the most common diagnosis. Using bevacizumab as first\u2010line treatment, with aflibercept reserved for resistant cases from 2013, eventually resulted in a nearly 1:1 ratio in drug usage.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aos.14177","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T04:18:33Z","timestamp":1562041113000},"page":"774-779","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Thirteen years of intravitreal anti\u2010vascular endothelial growth factor therapy: the promises and burdens of a paradigm shift told from the perspective of the largest retina service in Norway."],"prefix":"10.1111","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1259-0653","authenticated-orcid":false,"given":"\u00d8ystein Kalsnes","family":"J\u00f8rstad","sequence":"first","affiliation":[{"name":"Department of Ophthalmology Oslo University Hospital Norway"},{"name":"Faculty of Medicine University of Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif Arthur","family":"Steffensen","sequence":"additional","affiliation":[{"name":"Section for Administrative processes Oslo University Hospital Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketil","family":"Eriksen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Oslo University Hospital Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnhei\u00f0ur","family":"Bragad\u00f3ttir","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Oslo University Hospital Norway"},{"name":"Faculty of Medicine University of Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Carstens","family":"Moe","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Oslo University Hospital Norway"},{"name":"Faculty of Medicine University of Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.041"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.018"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13522"},{"key":"e_1_2_5_5_1","volume-title":"The innovator's dilemma: when new technologies cause great firms to fail","author":"Christensen CM","year":"1997"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414264"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13824"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12681"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13480"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.06.006"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12371"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20525-8"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.02.024"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faos.14177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aos.14177","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T21:57:23Z","timestamp":1693864643000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.14177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/aos.14177"],"URL":"https:\/\/doi.org\/10.1111\/aos.14177","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"2019-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}